Clinical effect of eltrombopag (Revlan) in the treatment of thrombocytopenia

Eltrombopag is an oral thrombopoietin receptor agonist (TPO-RA) that stimulates the differentiation and maturation of megakaryocytes in the bone marrow, thereby promoting platelet production. The drug is mainly used to treat diseases such as chronic immune thrombocytopenia (ITP), hepatitis C-related thrombocytopenia, and aplastic anemia. Unlike traditional hormone or immunosuppressive treatments, eltrombopag can directly act on the hematopoietic system, improve platelet production from the source, and provide a new treatment option for patients with long-term thrombocytopenia.

The clinical efficacy of eltrombopag has been widely verified in patients with chronicITP. Multiple phase III studies have shown that about 70% to 80% of patients 2 to 3 weeks after taking the drug. The platelet count increased significantly, and some patients could even maintain it stable within the safe range (≥50×10⁹/L), thereby significantly reducing the risk of bleeding and the need for blood transfusions. Compared with corticosteroids, eltrombopag can maintain platelet levels longer without increasing the risk of severe infection or immunosuppression, bringing a new long-term control method to patients with refractory ITP.

Eltrombopag also showed good efficacy in patients with thrombocytopenia associated with hepatitis C. Clinical data shows that the use of this drug can effectively increase platelet counts, allowing patients to successfully receive antiviral treatment or invasive procedures without increasing the risk of bleeding. Especially in patients who are unable to undergo platelet transfusion or whose blood transfusion results are unsatisfactory, the oral convenience and sustained platelet elevating effect of eltrombopag have significantly improved treatment compliance and quality of life.

In addition, in severe aplastic anemia, eltrombopag is often used as an adjuvant treatment in combination with immunosuppressive therapy to promote multi-lineage hematopoietic recovery. Some studies have shown that after several months of continuous treatment, not only the platelet count increases, but the red blood cells and neutrophils can also be improved, suggesting that it may have a broad-spectrum hematopoietic stimulating effect. Overall, eltrombopag has a definite plate-raising effect, good tolerance and low risk of serious adverse reactions, and has become an important treatment option for various thrombocytopenias. However, liver function and blood images still need to be monitored under the guidance of a doctor to ensure safe use.

Reference materials:https://www.drugs.com/